We believe exposure to SEP-regulated products aided AIP in mitigating against the weaker economy.
We show that the continual rise in chronic kidney failure could be a potential opportunity for AIP to expand operations. Although the NHI is far from implementation, we show an example of a capitation model proposed by the bill in action.
